Literature DB >> 17431406

Development trends for monoclonal antibody cancer therapeutics.

Janice M Reichert1, Viia E Valge-Archer.   

Abstract

Monoclonal antibodies are now established as a key therapeutic modality for a range of diseases. Owing to the ability of these agents to selectively target tumour cells, cancer has been a major focus of development programmes for monoclonal antibodies so far. Here, we overview trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980, with the aim of informing future research and development for this class of therapeutics.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17431406     DOI： 10.1038/nrd2241

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  125 in total

1.  Rabbit monoclonal antibody: potential application in cancer therapy.

Authors:  Lifeng Feng; Xian Wang; Hongchuan Jin
Journal:  Am J Transl Res       Date:  2011-04-23       Impact factor: 4.060

Review 2.  Hurdles in anticancer drug development from a regulatory perspective.

Authors:  Bertil Jonsson; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

3.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

Review 4.  Selection and characterization of cell binding and internalizing phage antibodies.

Authors:  Yu Zhou; Lequn Zhao; James D Marks
Journal:  Arch Biochem Biophys       Date:  2012-05-22       Impact factor: 4.013

5.  RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB.

Authors:  Yang Zhong Huang; Frank J Hernandez; Bin Gu; Katie R Stockdale; Kishore Nanapaneni; Todd E Scheetz; Mark A Behlke; Andrew S Peek; Thomas Bair; Paloma H Giangrande; James O McNamara
Journal:  Mol Pharmacol       Date:  2012-06-29       Impact factor: 4.436

Review 6.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

7.  In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.

Authors:  Giorgio Zauli; Federica Corallini; Sonia Zorzet; Vittorio Grill; Roberto Marzari; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-08-17       Impact factor: 3.850

Review 8.  Recovery and purification process development for monoclonal antibody production.

Authors:  Hui F Liu; Junfen Ma; Charles Winter; Robert Bayer
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 9.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.